Turbulent boundary layer around a group of obstacles in the direction of flow

Results of an investigation of a boundary layer in a turbulent flow on the surface of a wall having a group of obstacles on the path of flow are presented with regard to the mean velocity field, velocity distribution of the two dimensional flow, wall surface shear stresses and Reynolds stresses measured in a downstream cross section where an interference of boundary layers takes place in a flow around adjacent obstacles arranged on the path of flow

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.

ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre, randomised, double-blind, parallel-group, placebo-controlled phase 3 study in Japan. Patients with RA aged ≥20 years receiving csDMARDs were randomly assigned (1:1:1) to denosumab 60 mg every 3 months (Q3M), denosumab 60 mg every 6 months (Q6M) or placebo. The change in the modified total Sharp score (mTSS) and effect on bone mineral density (BMD) at 12 months was evaluated.ResultsIn total, 654 patients received the trial drugs. Denosumab groups showed significantly less progression of joint destruction. The mean changes in the mTSS at 12 months were 1.49 (95% CI 0.99 to 1.99) in the placebo group, 0.99 (95% CI 0.49 to 1.49) in the Q6M group (p=0.0235) and 0.72 (95% CI 0.41 to 1.03) in the Q3M group (p=0.0055). The mean changes in bone erosion score were 0.98 (95% CI 0.65 to 1.31) in the placebo group, 0.51 (95% CI 0.22 to 0.80) in the Q6M group (p=0.0104) and 0.22 (95% CI 0.09 to 0.34) in the Q3M group (p=0.0001). No significant between-group difference was observed in the joint space narrowing score. The per cent change in lumbar spine (L1-L4) BMD in the placebo, Q6M and Q3M groups were -1.03%, 3.99% (p<0.0001) and 4.88% (p<0.0001). No major differences were observed among safety profiles.ConclusionsDenosumab inhibits the progression of joint destruction, increases BMD and is well tolerated in patients with RA taking csDMARD

Infrared photodissociation spectroscopy of H+•(CH3COOH)n and H+•(CH3COOH)n•H2O (n=1–5)

第17回化学反応討論会, 2001年5月23日-26日, 九州大学箱崎キャンパス(福岡

Infrared photodissociation spectroscopy of H+•(CH3COOH)n and H+•(CH3COOH)n•H2O (n=1–5)

第17回化学反応討論会, 2001年5月23日-26日, 九州大学箱崎キャンパス(福岡

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial

OBJECTIVES: To evaluate efficacy and safety of three different regimens of denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), for Japanese patients with rheumatoid arthritis (RA). METHODS: In this multicentre, randomised, placebo-controlled phase II study, 350 Japanese patients with RA between 6 months and <5 years, stratified by glucocorticoid use and rheumatoid factor status, were randomly assigned to subcutaneous injections of placebo or denosumab 60 mg every 6 months (Q6M), every 3 months (Q3M) or every 2 months (Q2M). All patients basically continued methotrexate treatment and had a supplement of calcium and vitamin D throughout the study. The primary endpoint was change in the modified Sharp erosion score from baseline to 12 months. RESULTS: Denosumab significantly inhibited the progression of bone erosion at 12 months compared with the placebo, and the mean changes of the modified Sharp erosion score at 12 months from baseline were 0.99, 0.27 (compared with placebo, p=0.0082), 0.14 (p=0.0036) and 0.09 (p<0.0001) in the placebo, Q6M, Q3M and Q2M, respectively. Secondary endpoint analysis revealed that denosumab also significantly inhibited the increase of the modified total Sharp score compared with the placebo, with no obvious evidence of an effect on joint space narrowing for denosumab. As shown in previous studies, denosumab increased bone mineral density. No apparent difference was observed in the safety profiles of denosumab and placebo. CONCLUSIONS: Addition of denosumab to methotrexate has potential as a new therapeutic option for patients with RA with risk factors of joint destruction. TRIAL REGISTRATION NUMBER: JapicCTI-101263

Formation and Annihilation Dynamics of Benzene Cluster Cations in Neat Liquid Benzene

第13回化学反応討論会, 1997年5月28日-30日, 北陸先端大学・石川ハイテク交流センター(金沢

Infrared photoinduced evaporation of benzene cluster ions

第16回化学反応討論会, 2000年6月1日-3日, サタケ講堂(東広島

The ground state of Sr3Ru2O7 revisited; Fermi liquid close to a ferromagnetic instability

We show that single-crystalline Sr3Ru2O7 grown by a floating-zone technique is an isotropic paramagnet and a quasi-two dimensional metal as spin-triplet superconducting Sr2RuO4 is. The ground state is Fermi liquid with very low residual resistivity (3 micro ohm cm for in-plane currents) and a nearly ferromagnetic metal with the largest Wilson ratio Rw>10 among paramagnets so far. This contrasts with the ferromagnetic order at Tc=104 K reported on single crystals grown by a flux method [Cao et al., Phys. Rev. B 55, R672 (1997)]. We have also found a dramatic changeover from paramagnetism to ferromagnetism under applied pressure. This suggests the existence of a substantial ferromagnetic instability on the verge of a quantum phase transition in the Fermi liquid state.Comment: 5 pages, 4 figures, to be published in Phys. Rev. B : Rapid co

The changing landscape of biosimilars in rheumatology

Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval